Pharmatest to present novel oncology models at Tri-Con 2015
Press Release | Pharmatest Services Ltd
FEBRUARY 04, 2015
Turku, Finland: – Oncology and skeletal disease specialist CRO Pharmatest Services will present novel clinically predictive preclinical efficacy models for oncology drug development to a landmark scientific conference in San Francisco.
Pharmatest Services will attend the annual Cambridge Health tech Institute conference on February 16 – 18, which will focus on Predictive Preclinical Models in Oncology. The conference is part of the “Cancer Channel” of the 22nd Annual Molecular Medicine Tri-Conference (Tri-Con).
Preclinical efficacy models
Pharmatest is scheduled to deliver two scientific presentations to the conference, demonstrating development of novel clinically predictive preclinical efficacy models for oncology drug development.
Pharmatest will also be an exhibitor at the conference, fielding an expert team at Booth 100 at the Moscone North Convention Center, including its COO Dr. Jukka Rissanen and one of its research directors Dr. Jenni Bernoulli.
Delegates to the conference can pre-book meetings with the Pharmatest team by emailing the company here.
About Pharmatest Services
Pharmatest Services Ltd (Pharmatest) is a contract research organisation (CRO) specializing in clinically predictive preclinical efficacy services in the therapeutic areas of oncology and skeletal diseases.
Pharmatest helps establish proof-of-efficacy of cancer drug candidates with cell culture assays, organotypic 3D models, orthotopic animal models, and disseminated cancer models. Its models of skeletal diseases include bone cell culture assays and animal models of osteoporosis and osteoarthritis that can also be used for bone safety testing.
Headquartered in Turku, Finland, Pharmatest’s preclinical research unit offers modern research facilities including fully equipped laboratories and barrier-type animal facilities.
About Tri-Con 2015
The 22nd International Molecular Medicine Tri-Conference is one of the pharmaceutical industry’s most influential events in Molecular Medicine, focusing on Drug Discovery, Genomics, Diagnostics and Information Technology. The 2015 Tri-Con, scheduled over six days between February 15 and 20, features an expanded program including six symposia, more than 20 short courses, and 17 conference programs.
Tri-Consits at the center of a global network, linking scientists in some 40 countries. The 2015 event is expected to attract more than 3,000 delegates and will feature some 500 speakers representing the full range of organizations and research fields. It will also feature more than 400 presentations and panel discussions.
A key element of Tri-Con will be the third annual Cambridge Health Institute Predictive Preclinical Models in Oncology Conference designed to highlight cutting-edge in vitro and in vivo preclinical tumor models and to facilitate discussions about effective translational approaches in cancer research.
More information at http://www.triconference.com/Pre-Clinical-Oncology-Models and at http://www.triconference.com
Jussi Halleen; CEO, Pharmatest Services Ltd.
Tel.: + 358 50 380 9551
Click on Pharmatest to present novel oncology models at Tri-Con 2015 for other information.
Click on Pharmatest to contact the company directly.